Aspirin

Direct oral anticoagulants vs. aspirin in patients needing ablation for ventricular tachycardia.

Dual antiplatelet therapy for 1 month vs. 3 or more months in patients at high bleeding risk who had PCI with a biodegradable-polymer sirolimus-eluting stent (Ultimaster, Terumo).

Despite fewer bleeding events, 1-month dual antiplatelet therapy with clopidogrel failed to prove noninferiority vs. 12-month DAPT after PCI and stent implantation for ACS, according to a presenter.

In patients at high bleeding risk, dual antiplatelet therapy for 1 month after PCI lowered bleeding rates and was noninferior for ischemic events compared with 3-month DAPT, according to results of the MASTER DAPT trial.

Results of a study showed aspirin was linked with lower rates of early, deep prosthetic joint infection after primary total knee arthroplasty vs. non-aspirin chemoprophylaxis, a presenter said.

Among patients who underwent left ventricular arrhythmia ablation with a radiofrequency catheter, direct oral anticoagulants were superior to aspirin in preventing cerebrovascular events, according to the results of the STROKE-VT trial.

The “ABCs” have provided a roadmap for primary and secondary CVD prevention since 1999, according to a speaker at the virtual American Society for Preventive Cardiology Congress on CVD Prevention.

The American Gastroenterological Association published a clinical practice update to describe the role of medications for the chemoprevention of colorectal neoplasia.

The ADAPTABLE trial, presented and published in May, was notable in two ways: It provided answers on aspirin dosage for patients needing secondary CVD prevention and it showed a large-scale pragmatic trial could work.

Regardless of patient age, switching from dual antiplatelet therapy to ticagrelor monotherapy after 3 months of ticagrelor plus aspirin reduces bleeding without increasing ischemic events, according to new data from the TWILIGHT trial.